Telehealth & Digital Health

With leadership buying shares and promising trial data for its novel cancer drug, MAIA Biotechnology is sending strong signals to investors. What's next?

A new rapid saliva test from ImpetusDX promises to revolutionize oral care by linking gum health to systemic disease, but can it overcome market hurdles?

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

A new campaign tackles undiagnosed kidney disease. But is it just public health, or a savvy strategy to reshape a multi-billion dollar market?

Daré Bioscience is targeting a 20M-woman market with a novel arousal cream. This is the story of its clever regulatory strategy and high-stakes bet.

A Chinese biotech is pioneering next-gen cancer drugs that promise higher precision and fewer side effects. Is this the future of oncology treatment?

The creator economy has mastered ROI-driven engagement. Can healthcare use its AI-powered playbook to improve patient outcomes and combat misinformation?

An Atlanta clinic's top award highlights a market shift toward minimally invasive fibroid treatment and a crucial fight for health equity in women's care.

A landmark demonstration of 'unhackable' quantum communication on a live network signals a paradigm shift for protecting sensitive healthcare data.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

Dr. Timothy Lubenow's move from a top university to a community clinic highlights a trend that's making advanced medical care more accessible.

A Pennsylvania health system is partnering with an online platform to fast-track nurses, a model that could be a blueprint for a nation in crisis.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

FDA clears Phase IIb trial for CS1, an epigenetic drug aiming to reverse PAH damage, not just manage symptoms, signaling a major market and patient shift.

The ADA’s new standards push for tech from day one and holistic care, but can the system deliver this innovative future to every patient?

A new partnership aims to advance a novel antibody for FTLD, a devastating dementia, showcasing a powerful model for biotech innovation and strategic growth.

SS Innovations is betting its cost-efficient SSi Mantra robot can break into the U.S. market. Will affordability democratize the operating room?

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.